What Bristol Myers Squibb Foundation does

The Bristol Myers Squibb Foundation is the charitable arm of Bristol-Myers Squibb Company, a publicly traded global biopharmaceutical company (NYSE: BMY). It is a private nonprofit organization headquartered in the United States, with a stated mission to promote health equity and improve health outcomes of underserved populations. The Foundation concentrates its work on two principal program areas: strengthening cancer care delivery in Africa through partnership-based initiatives, and expanding access to life-saving medicines in low- and middle-income countries (LMICs). Programming is structured around the parent company's therapeutic footprint — oncology, hematology, cardiovascular disease — and is delivered through collaborations with healthcare institutions, research organizations, and patient-advocacy groups operating in regions where BMS has limited direct commercial footprint.

The Foundation does not sell products, license intellectual property, or generate commercial revenue. Its funding flows are tied to the parent company's corporate giving and social-impact commitments, and its operational infrastructure is governed under US nonprofit regulation with oversight anchored to Bristol-Myers Squibb Company. The Foundation's technology stack is limited to standard corporate communications, social media engagement, and CRM-driven outreach; advanced capabilities such as AI-driven protein degradation drug discovery referenced in input data are characteristics of the parent biopharmaceutical company, not the Foundation. The Foundation serves three principal beneficiary groups: patients in underserved regions (particularly in Africa and LMICs), healthcare institutions delivering cancer and specialty care in those regions, and broader patient-advocacy and research communities aligned with parent-company therapeutic priorities.

From a business-model perspective, the Foundation functions as a grantmaking and program-delivery vehicle. It does not capture pricing economics, GTM motion, or distribution in the conventional commercial sense; instead, it leverages the parent's global brand recognition, regulatory standing as a 501(c)-aligned entity, and reach through partners to execute health-equity programming. Revenue, budget, and grant-disbursement figures are not disclosed in the input data, leaving financial scale unverified. The Foundation is operationally active and positioned within BMS's broader corporate-responsibility and population-health stack, with continuity tied to the strategic priorities and resourcing capacity of the parent company.

Name

Bristol Myers Squibb Foundation

Legal name

Bristol Myers Squibb Foundation

Website

https://bms.com

Company type

Private

Operating status

Operating

Short description

The Bristol Myers Squibb Foundation is the charitable arm of Bristol-Myers Squibb Company, a private nonprofit that promotes health equity and improves health outcomes for underserved populations through partnerships strengthening cancer care in Africa and expanding access to life-saving medicines in low- and middle-income countries.

Ownership category

akta.pro rank

Product category

Health Equity Philanthropy

NAICS

Grantmaking Foundations (813211), Voluntary Health Organizations (813212), Grantmaking and Giving Services (81321)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industries

Community Health, Prevention & Health Education (BPAGACAC), Global Health Financing Mechanisms & Pooled Funds (HLAJAOAC), Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Health equity philanthropy
• Cancer care access
• Global health grants
• Patient access programs
• Underserved populations

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Revenue model

1. Pharmaceutical Product Sales: BMS generates revenue primarily through the sale of prescription biopharmaceutical medicines across its therapeutic areas including oncology, hematology, neuroscience, immunology, and cardiovascular diseases. Products include established brands like OPDIVO, YERVOY, REVLIMID, ELIQUIS, and others.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

The Bristol Myers Squibb Foundation is the charitable foundation of Bristol-Myers Squibb Company, focused on promoting health equity and improving health outcomes for underserved populations. It funds partnership-driven programs that strengthen cancer care in regions such as Africa and expand access to life-saving medicines in low- and middle-income countries. The Foundation does not sell commercial products or services; its offerings consist of grant-funded initiatives and institutional partnerships aligned with the parent company's corporate responsibility agenda.

Product overview

Bristol Myers Squibb is a global biopharmaceutical company offering a diverse portfolio of medicines across multiple therapeutic areas including Oncology, Hematology, Neuroscience, Immunology, and Cardiovascular diseases. The company provides both proprietary small molecule drugs and biologic therapies including CAR T-cell therapies. Key products include OPDIVO® and YERVOY® (immunotherapies), ELIQUIS® (anticoagulant), REVLIMID® and POMALYST® (immunomodulatory agents), and innovative cell therapies like ABECMA® and BREYANZI®. The portfolio spans oral, injectable, and infusion formulations targeting serious diseases including various cancers, autoimmune conditions, and cardiovascular diseases. BMS also develops investigational medicines through a pipeline of 50+ compounds across 40+ disease areas.

Differentiator

Problem solved

Functional benefit

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration10 records

AI capability2 records

Feature2 records

Partnerships

One partnership is on record.

• Healthcare Institutions and Research OrganizationscoreStrategic or Co-development PartnerBMS partners with healthcare institutions, universities, and research organizations globally to conduct clinical trials, collaborative research projects, and clinical studies. These partnerships support drug development across oncology, hematology, neuroscience, immunology, and cardiovascular therapeutic areas.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Pfizer Foundation: Philanthropic arm of Pfizer focused on global health equity, infectious disease, and access-to-medicines initiatives. Directly comparable as another large-cap pharma corporate foundation pursuing health-equity programming in LMICs.
• AbbVie Foundation: Philanthropic arm of AbbVie supporting health equity, patient access, and community health programs. Comparable corporate-foundation structure and health-equity framing.
• Eli Lilly Foundation: Foundation of Eli Lilly focused on diabetes, oncology and health-equity programs domestically and globally. Comparable scale, therapeutic focus, and parent-foundation governance.
• Roche Foundation: Roche-affiliated philanthropic entity supporting health access and cancer care initiatives. Comparable therapeutic alignment (oncology focus) and foundation model.
• Merck Foundation: Philanthropic arm of Merck & Co. focused on global health, oncology access, and health workforce capacity building in underserved regions. Comparable mission, structure, and target geographies to BMS Foundation.
• Johnson & Johnson Foundation: Philanthropic arm of J&J operating global health equity programs spanning health workforce, women/children, and infectious disease. Closely comparable in scale, parent backing, and LMIC focus.
• Sanofi Foundation: Sanofi's philanthropic vehicle focused on health equity and access in underserved communities. Comparable structure and LMIC orientation to BMS Foundation.
• Gilead Foundation: Foundation arm of Gilead Sciences funding HIV, viral hepatitis, and oncology equity initiatives. Comparable structure as a vertically focused biopharma-affiliated grantmaker.
• Novartis Foundation: Novartis-affiliated foundation operating population-health and NCD programs in LMICs. Comparable global-health-equity mandate and operating geographies.

Broad incumbents

• Bill & Melinda Gates Foundation: Largest private health-equity funder globally with deep LMIC health-system investments. Not a corporate foundation, but serves as a benchmark funder/partner shaping the same global health equity space BMS Foundation operates in.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xtwitter.com/BMSNEWS
• YouTubeyoutube.com/bristolmyerssquibb
• Facebookfacebook.com/BristolMyersSquibb
• LinkedInlinkedin.com/company/bristol-myers-squibb
• Instagraminstagram.com/bristolmyerssquibb

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bristol Myers Squibb Foundation